What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies?
The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming increasingly crowded. In recent years, several new, high-priced therapies have been approved for use in this patient population, making this lucrative market more dynamic and competitive. The launch of ibrutinib (Johnson & Johnson/Janssen/Pharmacyclics’ Imbruvica) and idelalisib (Gilead Sciences’ Zydelig) in 2014 transformed the treatment algorithm and improved the outlook for patients. Nevertheless, clinical and commercial opportunity awaits emerging therapies that can provide greater survival benefits than the current standards of care and add minimal toxicities to the existing chemotherapy regimens used to treat first-line CLL/SLL.